Insmed(US:INSM) investorplace.comยท2024-05-28 12:40Core Insights - Insmed's stock is experiencing a significant rise following positive Phase 3 clinical trial results for brensocatib in patients with non-cystic fibrosis bronchiectasis, achieving its primary endpoint of statistically significant reductions in the annualized rate of pulmonary exacerbations compared to placebo [1][3] - The study also met several secondary endpoints, indicating the potential effectiveness of brensocatib as a treatment option [1][3] Company Developments - Insmed plans to submit a New Drug Application (NDA) for brensocatib to the FDA in Q1 2024, aiming for a commercial launch in mid-2025 [3][4] - Following the NDA submission, the drug is expected to be released in Europe and Japan in 2026 [4] Market Reaction - The stock has seen heavy trading, with over 4.1 million shares traded, significantly above its daily average of approximately 1.8 million shares [4] - As of Tuesday morning, Insmed's stock price has increased by 133.6% [4]